{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:28:38Z","timestamp":1790710118671,"version":"4.1.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23 DK107937, R01 DK97830, P30 DK19525"],"award-info":[{"award-number":["K23 DK107937, R01 DK97830, P30 DK19525"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001878"],"award-info":[{"award-number":["UL1 TR001878"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019606","name":"Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Insulin secretion within 30 minutes of nutrient ingestion is reduced in people with cystic fibrosis (PwCF) and pancreatic insufficiency and declines with worsening glucose tolerance. The glucose potentiated arginine (GPA) test is validated for quantifying \u03b2-cell secretory capacity as an estimate of functional \u03b2-cell mass but requires technical expertise and is burdensome. This study sought to compare insulin secretion during mixed-meal tolerance testing (MMTT) to GPA-derived parameters in PwCF.<\/jats:p><jats:sec><jats:title>Methods<\/jats:title><jats:p>Secondary data analysis of CF-focused prospective studies was performed in PwCF categorized as 1) pancreatic insufficient [PI-CF] or 2) pancreatic sufficient [PS-CF] and in 3) non-CF controls. MMTT: insulin secretory rates (ISR) were derived by parametric deconvolution using 2-compartment model of C-peptide kinetics, and incremental area under the curve (AUC) was calculated for 30, 60 and 180-minutes. GPA: acute insulin (AIR) and C-peptide responses (ACR) were calculated as average post-arginine insulin or C-peptide response minus pre-arginine insulin or C-peptide under fasting (AIR<jats:sub>arg<\/jats:sub> and ACR<jats:sub>arg<\/jats:sub>), ~230 mg\/dL (AIR<jats:sub>pot<\/jats:sub> and ACR<jats:sub>pot<\/jats:sub>), and ~340 mg\/dL (AIR<jats:sub>max<\/jats:sub> and ACR<jats:sub>max<\/jats:sub>) hyperglycemic clamp conditions. Relationships of MMTT to GPA parameters were derived using Pearson\u2019s correlation coefficient. Predicted values were generated for MMTT ISR and compared to GPA parameters using Bland Altman analysis to assess degree of concordance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>85 PwCF (45 female; 75 PI-CF and 10 PS-CF) median (range) age 23 (6-56) years with BMI 23 (13-34) kg\/m<jats:sup>2<\/jats:sup>, HbA<jats:sub>1c<\/jats:sub> 5.5 (3.8-10.2)%, and FEV1%-predicted 88 (26-125) and 4 non-CF controls of similar age and BMI were included. ISR AUC<jats:sub>30min<\/jats:sub> positively correlated with AIR<jats:sub>arg<\/jats:sub> (<jats:italic>r<\/jats:italic>=0.55), AIR<jats:sub>pot<\/jats:sub> (<jats:italic>r<\/jats:italic>=0.62), and AIR<jats:sub>max<\/jats:sub> (<jats:italic>r<\/jats:italic>=0.46) and with ACR<jats:sub>arg<\/jats:sub> (<jats:italic>r<\/jats:italic>=0.59), ACR<jats:sub>pot<\/jats:sub> (<jats:italic>r<\/jats:italic>=0.60), and ACR<jats:sub>max<\/jats:sub> (<jats:italic>r<\/jats:italic>=0.51) (all <jats:italic>P<\/jats:italic>&amp;lt;0.001). ISR AUC<jats:sub>30min<\/jats:sub> strongly predicted AIR<jats:sub>arg<\/jats:sub> (concordance=0.86), AIR<jats:sub>pot<\/jats:sub> (concordance=0.89), and AIR<jats:sub>max<\/jats:sub> (concordance=0.76) at lower mean GPA values, but underestimated AIR<jats:sub>arg<\/jats:sub>, AIR<jats:sub>pot<\/jats:sub>, and AIR<jats:sub>max<\/jats:sub> at higher GPA-defined \u03b2-cell secretory capacity. Between test agreement was unaltered by adjustment for study group, OGTT glucose category, and BMI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Early-phase insulin secretion during MMTT can accurately predict GPA-derived measures of \u03b2-cell function and secretory capacity when functional \u03b2-cell mass is reduced. These data can inform future multicenter studies requiring reliable, standardized, and technically feasible testing mechanisms to quantify \u03b2-cell function and secretory capacity.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1340346","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T05:27:25Z","timestamp":1708406845000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Early-phase insulin secretion during mixed-meal tolerance testing predicts \u03b2-cell function and secretory capacity in cystic fibrosis"],"prefix":"10.3389","volume":"15","author":[{"given":"Saba","family":"Sheikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darko","family":"Stefanovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa J.","family":"Kilberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Hadjiliadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald C.","family":"Rubenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Rickels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"B1","volume-title":"Cystic Fibrosis Foundation Patient Registry Annual Data Report 2021","year":"2022"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S002","article-title":"2. Classification and diagnosis of diabetes: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2004.12.039","article-title":"Epidemiology of cystic fibrosis-related diabetes","volume":"146","author":"Marshall","year":"2005","journal-title":"J Pediatr"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2337\/db16-0394","article-title":"Reduced beta-Cell Secretory Capacity in Pancreatic-Insufficient, but Not Pancreatic-Sufficient, Cystic Fibrosis Despite Normal Glucose Tolerance","volume":"66","author":"Sheikh","year":"2017","journal-title":"Diabetes"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12700","article-title":"beta-Cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1-hour oral glucose tolerance test glucose >\/=155 mg\/dL","volume":"19","author":"Nyirjesy","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2013.02.008","article-title":"Update on cystic fibrosis-related diabetes","volume":"12","author":"Kelly","year":"2013","journal-title":"J Cyst Fibros"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-020-05210-8","article-title":"A tale of two pancreases: exocrine pathology and endocrine dysfunction","volume":"63","author":"Rickels","year":"2020","journal-title":"Diabetologia"},{"key":"B9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1463-1326.2008.00945.x","article-title":"An examination of beta-cell function measures and their potential use for estimating beta-cell mass","author":"Kahn","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201806-1018OC","article-title":"Islet hormone and incretin secretion in cystic fibrosis after four months of ivacaftor therapy","volume":"199","author":"Kelly","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab365","article-title":"Effect of sitagliptin on islet function in pancreatic insufficient cystic fibrosis with abnormal glucose tolerance","volume":"106","author":"Kelly","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2337\/db22-0399","article-title":"Effects of GLP-1 and GIP on islet function in glucose-intolerant, pancreatic-insufficient cystic fibrosis","volume":"71","author":"Nyirjesy","year":"2022","journal-title":"Diabetes"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2337\/db13-1198","article-title":"The oral minimal model method","volume":"63","author":"Cobelli","year":"2014","journal-title":"Diabetes"},{"key":"B14","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation","author":"Farrell","year":"2017","journal-title":"J Pediatr"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2337\/db07-1124","article-title":"Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance","volume":"57","author":"Vollmer","year":"2008","journal-title":"Diabetes"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115779","article-title":"Effects of hemipancreatectomy on pancreatic alpha and beta cell function in healthy human donors","volume":"89","author":"Seaquist","year":"1992","journal-title":"J Clin Invest"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00325.2002","article-title":"Improved beta-cell function after standardized weight reduction in severely obese subjects","volume":"284","author":"Guldstrand","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0398","article-title":"Effect of exenatide, sitagliptin, or glimepiride on beta-cell secretory capacity in early type 2 diabetes","volume":"37","author":"Gudipaty","year":"2014","journal-title":"Diabetes Care"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1984.246.5.E405","article-title":"Adaptation of B and A cell function during prolonged glucose infusion in human subjects","volume":"246","author":"Ward","year":"1984","journal-title":"Am J Physiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s001250050986","article-title":"Glucose-dependent arginine stimulation test for characterization of islet function: studies on reproducibility and priming effect of arginine","volume":"41","author":"Larsson","year":"1998","journal-title":"Diabetologia"},{"key":"B21","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.1152\/ajpendo.2001.280.1.E2","article-title":"Quantitative indexes of beta-cell function during graded up&down glucose infusion from C-peptide minimal models","volume":"280","author":"Toffolo","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00149.2014","article-title":"Arginine is preferred to glucagon for stimulation testing of beta-cell function","volume":"307","author":"Robertson","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111542","article-title":"Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus","volume":"74","author":"Ward","year":"1984","journal-title":"J Clin Invest"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1991.tb01806.x","article-title":"Decreased insulin secretory capacity and normal pancreatic B-cell glucose sensitivity in non-obese patients with NIDDM","volume":"21","author":"Van Haeften","year":"1991","journal-title":"Eur J Clin Invest"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e3295","DOI":"10.1002\/dmrr.3295","article-title":"Different beta-cell secretory phenotype in non-obese compared to obese early type 2 diabetes","volume":"36","author":"Gudipaty","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.4.951","article-title":"Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose","volume":"51","author":"Greenbaum","year":"2002","journal-title":"Diabetes"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2289","article-title":"{beta}-Cell secretory capacity and demand in recipients of islet, pancreas, and kidney transplants","volume":"95","author":"Rickels","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000287595.16442.a7","article-title":"Acute insulin responses to glucose and arginine as predictors of beta-cell secretory capacity in human islet transplantation","volume":"84","author":"Rickels","year":"2007","journal-title":"Transplantation"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2011.11.001","article-title":"Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus","volume":"11","author":"Hillman","year":"2012","journal-title":"J Cyst Fibros"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2460","article-title":"Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis\u2013effects of pancreatic enzyme supplementation","volume":"96","author":"Kuo","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1211750","article-title":"Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes","volume":"105","author":"Nauck","year":"1997","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-4417","article-title":"Pancreatic enzyme supplementation improves the incretin hormone response and attenuates postprandial glycemia in adolescents with cystic fibrosis: a randomized crossover trial","volume":"99","author":"Perano","year":"2014","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1340346\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T05:27:28Z","timestamp":1708406848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1340346\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":32,"alternative-id":["10.3389\/fendo.2024.1340346"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1340346","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,20]]},"article-number":"1340346"}}